[HTML][HTML] Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
…, L Crinó, MJ Ahn, T De Pas, B Besse… - … England Journal of …, 2013 - Mass Medical Soc
Background In single-group studies, chromosomal rearrangements of the anaplastic lymphoma
kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an …
kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an …
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
…, C Rey, A Bougouin, S Cousin, S Le Moulec, B Besse… - Nature Cancer, 2021 - nature.com
Only a minority of patients derive long-term clinical benefit from anti-programmed cell death
protein 1 (anti-PD-1) or anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibodies…
protein 1 (anti-PD-1) or anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibodies…
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Small-cell lung cancer (SCLC) is an aggressive lung tumor subtype with poor prognosis 1 ,
2 , 3 . We sequenced 29 SCLC exomes, 2 genomes and 15 transcriptomes and found an …
2 , 3 . We sequenced 29 SCLC exomes, 2 genomes and 15 transcriptomes and found an …
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC
B Besse, M Charrier, V Lapierre, E Dansin… - …, 2016 - Taylor & Francis
Dendritic cell-derived exosomes (Dex) are small extracellular vesicles secreted by viable
dendritic cells. In the two phase-I trials that we conducted using the first generation of Dex (IFN-…
dendritic cells. In the two phase-I trials that we conducted using the first generation of Dex (IFN-…
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
…, CM Blakely, T Seto, BC Cho, D Tosi, B Besse… - The Lancet …, 2020 - thelancet.com
Background Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …
[HTML][HTML] 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease
B Besse, A Adjei, P Baas, P Meldgaard, M Nicolson… - Annals of …, 2014 - Elsevier
To complement the existing treatment guidelines for all tumour types, ESMO organises
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO …
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
…, BJ Solomon, R Chiari, GJ Riely, B Besse… - The Lancet …, 2019 - thelancet.com
Background Lorlatinib is a potent, brain-penetrant, third-generation tyrosine kinase inhibitor
(TKI) that targets ALK and ROS1 with preclinical activity against most known resistance …
(TKI) that targets ALK and ROS1 with preclinical activity against most known resistance …
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICIs)
in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, …
in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, …
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic …
Background The molecular profiling of patients with advanced non-small-cell lung cancer (NSCLC)
for known oncogenic drivers is recommended during routine care. Nationally, …
for known oncogenic drivers is recommended during routine care. Nationally, …
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
AT Shaw, E Felip, TM Bauer, B Besse… - The Lancet …, 2017 - thelancet.com
Background Most patients with anaplastic lymphoma kinase (ALK)-rearranged or ROS proto-oncogene
1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) are sensitive to …
1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) are sensitive to …
